Phase II trial of biweekly THP-COP therapy for patients with peripheral T-cell lymphomas.
Phase 2
Recruiting
- Conditions
- Peripheral T-cell lymphomas (PTCL,nos, AITL, ALK-negative ALCL)
- Registration Number
- JPRN-UMIN000018919
- Lead Sponsor
- Kanagawa Clinical Oncology study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Severe infection, active tuberculosis, uncontrollable diabetes mellitus under insulin treatment, or liver cirrhosis (2) Other active malignancy (except for in situ carcinoma in uterine cervix or basal cell carcinoma) (3) CNS involvement (4) Pregnant or breastfeeding women (5) Severe psychosis (6) HBs antigen positive (7) HBc antibody positive or HBs antibody positive, with HBV-DNA positive (8) HIV antibody positive or HTLV-1 antibody positive (9) Patients with difficult situation for study such as high-risk of gastrointestinal perforation/bleeding or surgical indication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year progression-free survival rate
- Secondary Outcome Measures
Name Time Method Complete remission rate, Overall survival rate, Toxicity